- Previous Close
4.1300 - Open
4.1500 - Bid 3.8800 x 200
- Ask 3.9200 x 100
- Day's Range
3.8501 - 4.1500 - 52 Week Range
2.9000 - 10.6000 - Volume
228,458 - Avg. Volume
237,470 - Market Cap (intraday)
80.137M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date Oct 28, 2024 - Nov 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 11, 2023
- 1y Target Est
3.50
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; customer support center; and direct mail/print, which includes brochures and postcards. The company was incorporated in 1996 and is headquartered in Delray Beach, Florida.
www.1800petmeds.com287
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: PETS
View More
Performance Overview: PETS
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PETS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PETS
View MoreValuation Measures
Market Cap
85.08M
Enterprise Value
40.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.31
Price/Book (mrq)
0.91
Enterprise Value/Revenue
0.15
Enterprise Value/EBITDA
7.41
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.95%
Return on Assets (ttm)
0.19%
Return on Equity (ttm)
-2.60%
Revenue (ttm)
270.77M
Net Income Avi to Common (ttm)
-2.57M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
45.99M
Total Debt/Equity (mrq)
1.41%
Levered Free Cash Flow (ttm)
-8.17M
Research Analysis: PETS
View MoreCompany Insights: PETS
PETS does not have Company Insights
Research Reports: PETS
View MoreLowering target price to $15.00
PETMED EXPRESS INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetRaising target price to $16.00
PETMED EXPRESS INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $15.00
PETMED EXPRESS INC has an Investment Rating of HOLD; a target price of $15.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about PETS?
PETMED EXPRESS INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingPrice Target